search
Back to results

Enhanced Recovery After Laparoscopic Colorectal Surgery

Primary Purpose

Rectal Cancer, Postoperative Pain

Status
Completed
Phase
Phase 4
Locations
Norway
Study Type
Interventional
Intervention
Bupivacaine Injection
Sponsored by
University Hospital of North Norway
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Rectal Cancer

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

*All patients undergoing laparoscopic abdominoperineal rectal amputation for rectal cancer * Age 18-100 years are eligible for enrollment in the study.

Exclusion Criteria

  • ASA IV,
  • BMI>35,
  • contraindication to spinal analgesia
  • allergy to any of the drugs used in this study protocol,
  • chronic use of opioids or steroids,
  • liver or renal impairment,
  • patients scheduled for synchronous laparoscopic liver metastatic surgery
  • inability to communicate in Norwegian.

Sites / Locations

  • University Hospital of North Norway

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Spinal

Placebo

Arm Description

Spinal anesthesia

Placebo spinal

Outcomes

Primary Outcome Measures

Nummeric rating scale (0-10), where 10 indicate worst possible pain.
Worst pain scores in the first 48 hrs.

Secondary Outcome Measures

Full Information

First Posted
June 1, 2022
Last Updated
December 21, 2022
Sponsor
University Hospital of North Norway
search

1. Study Identification

Unique Protocol Identification Number
NCT05406765
Brief Title
Enhanced Recovery After Laparoscopic Colorectal Surgery
Official Title
Spinal Analgesia for Laparoscopic Abdominoperineal Rectal Amputation Using an Enhanced Recovery After Surgery Program: a Randomized Double-blind Placebo-controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Completed
Study Start Date
January 1, 2022 (Actual)
Primary Completion Date
October 7, 2022 (Actual)
Study Completion Date
October 7, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital of North Norway

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Investigators would like to test the effects of spinal anesthesia as an adjunct to general anesthesia in patients undergoing laparoscopic abdominoperineal rectal amputation. Investigators hypothesize that spinal anesthesia as an adjunct to general anesthesia will reduce postoperative pain and opioid requirements.
Detailed Description
Effective pain management after laparoscopic rectal surgery is a fundamental requirement in an enhanced recovery after surgery program (ERAS). Opioids remain the mainstay for postsurgical pain despite well documented side effects including sedation, dizziness, nausea, vomiting, constipation, physical dependence, tolerance, and respiratory depression. Spinal analgesia as an adjunct to general anesthesia has not been studied in laparoscopic rectal surgery, but data from studies of patients undergoing colon cancer resection indicate a positive analgesic effect of spinal anesthesia as an adjunct to general anesthesia. When an ERAS program was used for laparoscopic colonic resection, It has been showed that an intrathecal mixture of bupivacaine and morphine was associated with less postoperative opioid consumption. In a more recent paper intrathecal morphine was a more effective method for treating postoperative pain in laparoscopic colon surgery than intravenous opioids within an ERAS program. In the present proposal the investigators would like to test the effects of spinal anesthesia as an adjunct to general anesthesia in patients undergoing laparoscopic abdominoperineal rectal amputation. It was hypothesized that spinal anesthesia as an adjunct to general anesthesia would reduce postoperative pain and opioid requirements.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rectal Cancer, Postoperative Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Randomization, allocation, and blinding: Randomization will be conducted by using sealed, opaque envelopes. An independent colleague at the Clinical Research Department will randomize these envelopes in blocks of 5. These envelopes will be stacked and stored outside the operating room. The upper envelope will be opened by the attending anesthesiologist when an included patient arrives in the operating theater. The patient, surgical team, nurses on the ward, and researcher team will be blinded. Only the attending anesthetic team will be aware of the randomization. They will be instructed not to tell the patient or any other health care worker which group the patient was allocated to.
Allocation
Randomized
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Spinal
Arm Type
Active Comparator
Arm Description
Spinal anesthesia
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo spinal
Intervention Type
Drug
Intervention Name(s)
Bupivacaine Injection
Other Intervention Name(s)
Marcain
Intervention Description
One group will receive bupivacaine 15 mg and morphine 100 ug intrathecally
Primary Outcome Measure Information:
Title
Nummeric rating scale (0-10), where 10 indicate worst possible pain.
Description
Worst pain scores in the first 48 hrs.
Time Frame
48 hours after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria *All patients undergoing laparoscopic abdominoperineal rectal amputation for rectal cancer * Age 18-100 years are eligible for enrollment in the study. Exclusion Criteria ASA IV, BMI>35, contraindication to spinal analgesia allergy to any of the drugs used in this study protocol, chronic use of opioids or steroids, liver or renal impairment, patients scheduled for synchronous laparoscopic liver metastatic surgery inability to communicate in Norwegian.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lars M Ytrebø, PhD
Organizational Affiliation
University Hospital of North Norway
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital of North Norway
City
Tromsø
State/Province
Troms
ZIP/Postal Code
9038
Country
Norway

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Enhanced Recovery After Laparoscopic Colorectal Surgery

We'll reach out to this number within 24 hrs